Physician profile
Deborah L Giorgi-Guarnieri
NPI 1710960034
$19,083.01
in general payments reported to CMS, 2019-2025
25 companies · $919 in 2025
The $919 reported for 2025 was more than what 86% of Forensic Psychiatry providers received nationally (typical 2025 total: $125).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14K · 2020: $1,436 · 2021: $574 · 2022: $589 · 2023: $528 · 2024: $757 · 2025: $919.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,203.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,203.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $13,494.98 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $1,558.29 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $633.52 | 2019-2025 | Rexulti, Nuedexta, Abilify Maintena |
| E.R. Squibb & Sons, L.L.C. | $627.93 | 2024-2025 | Cobenfy |
| Teva Pharmaceuticals USA, INC. | $368.56 | 2019-2024 | Austedo Xr, Austedo |
| Bausch Health US, LLC | $358.55 | 2019-2021 | |
| Avanir Pharmaceuticals, INC. | $234.06 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $214.21 | 2022-2024 | Spravato |
| Axsome Therapeutics, INC. | $212.10 | 2022-2025 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $202.92 | 2021-2025 | Caplyta |
| Abbvie INC. | $199.21 | 2021-2025 | |
| Lundbeck LLC | $194.69 | 2019-2025 | Rexulti |
| Noven Therapeutics, LLC | $177.44 | 2020-2024 | Secuado, Xelstrym |
| Corium, LLC | $122.58 | 2023 | Adlarity |
| Takeda Pharmaceuticals U.S.A., INC. | $115.90 | 2019-2025 | Trintellix |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $81.35 | 2021 | |
| Neurocrine Biosciences, INC. | $58.91 | 2019-2025 | |
| Vanda Pharmaceuticals INC. | $47.67 | 2019-2022 | |
| Alfasigma USA, INC. | $46.22 | 2021-2022 | |
| Adamas Pharmaceuticals, INC. | $35.14 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $27.62 | 2022 | |
| Harmony Biosciences LLC | $24.50 | 2025 | |
| Sumitomo Pharma America, INC. | $18.93 | 2023 | Latuda |
| Shire North American Group INC | $16.38 | 2019 | |
| Noven Pharmaceuticals, INC. | $11.35 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deborah Giorgi-Guarnieri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.